Role of Teplizumab, a Humanized Anti-CD3 Monoclonal Antibody, in Managing Newly Diagnosed Type 1 Diabetes: An Updated Systematic Review and Meta-Analysis
Authors' conclusion
The results of the meta-analysis support teplizumab as a promising disease-modifying therapy for newly diagnosed T1D.
Study context
- Population
- Patients with newly diagnosed T1D in RCTs7 reports from 6 studies
- Participants
- 834 patients
- Comparison
- Teplizumab vs placebo
- Outcome
- Change in AUC of C-peptide levels from baseline
Pooled result
As reported in the abstract
Reduction in AUC of C-peptide from baseline · 6, 12, 18 and 24 months
Placebo vs TeplizumabMD, nmol/L (CI)P value
6 months; greater reduction with placebo
0.07(0.01–0.13)
P = 0.0212 months; greater reduction with placebo
0.07(0.04–0.11)
P = 0.000118 months; greater reduction with placebo
0.10(0.06–0.14)
P < 0.0000124 months; greater reduction with placebo
0.07(0.01–0.14)
P = 0.03Further pooled results
| Outcome | OR |
|---|---|
| Decreased C-peptide response · 6, 12, 18 and 24 monthsTeplizumab vs Placebo · 6 months | 0.21 |
| Decreased C-peptide response · 6, 12, 18 and 24 monthsTeplizumab vs Placebo · 12 months | 0.17 |
| Decreased C-peptide response · 6, 12, 18 and 24 monthsTeplizumab vs Placebo · 18 months | 0.30 |
| Decreased C-peptide response · 6, 12, 18 and 24 monthsTeplizumab vs Placebo · 24 months | 0.12 |
Exogenous insulin use and glycaemic control · up to 18 months post-treatment
- Reduced use of exogenous insulin with maintenance of comparable glycemic control with teplizumab
Safety
- Teplizumab imparted higher risks of grade ≥3 adverse events, adverse events leading to discontinuation, nausea, rash and lymphopenia
Original publication
Role of Teplizumab, a Humanized Anti-CD3 Monoclonal Antibody, in Managing Newly Diagnosed Type 1 Diabetes: An Updated Systematic Review and Meta-Analysis. Endocr Pract. Published 20 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →